Evaluation of the Pathobiology of CALR-mutated MPN Cells
Wake Forest University Health Sciences · with Atrium Health Levine Cancer Institute, Brookdale University Hospital Medical Center · NCT06480591
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 35
- US sites recruiting
- 2
- Study start
- January 21, 2025
- Record last updated
- July 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
Being studied: Blood Draw
Conditions: Myeloproliferative Neoplasm
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
- Age ≥ 18 years at the time of enrollment
- Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
- CALR-positive genetic mutation
Exclusion Criteria
- Diagnosis of MPN with JAK2 V617F mutation
Recruiting US locations
Atrium Health Levine Cancer
Charlotte, NC 28204
Site contact: Courtney Schepel · (980) 292-0817 · Courtney.Schepel@atriumhealth.org
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, NC 27157
Site contact: Ruben Mesa, MD · 336-716-4618 · ruben.mesa@atriumhealth.org
Study contacts (from the official record)
- Courtney Schepel · (980) 292-0817 · Courtney.Schepel@atriumhealth.org
Similar studies in North Carolina
All healthy volunteers studies in North Carolina →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Nalmefene Implant in Healthy Subjects
ReacX Pharmaceuticals, Inc.
- Location
- Morrisville, NC
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study
University of North Carolina, Chapel Hill
- Location
- Chapel Hill, NC + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteers
Breastfeeding Intervention to Prevent Obesity Among Children
University of North Carolina, Greensboro
- Location
- Greensboro, NC + 1 other US site
- Eligibility basics
- Ages 0 mo+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Charlotte, NC + 7 other US sites
- Eligibility basics
- Ages 12–55